Albany, NY -- (SBWIRE) -- 03/29/2019 -- Venous Thromboembolism - Market Insights, Epidemiology and Market Forecast 2028

Venous thromboembolism (VTE) is more common in female than in males.

- The total number of symptomatic, nonfatal VTE events per annum was more than 465,000 cases of deep vein thrombosis (DVT) and more than 295,000 cases of pulmonary embolism (PE).
- Venous thromboembolism (VTE) is a common disorder with at least 250,000 new events occurring each year in the United States.
- There was an estimated annual average of 547,596 hospitalizations in which VTE was diagnosed, for patients aged 18 years or older for a period of (2007-2009).

(Albany, US) DelveInsight launched a new report on Venous Thromboembolism - Market Insights, Epidemiology and Market Forecast-2028

Key Benefits

- Venous thromboembolism report will help to develop Business Strategies by understanding the trends shaping and driving theVenous thromboembolism (VTE) market.
- Organize sales and marketing efforts by identifying the best opportunities for Venous thromboembolism (VTE) market.
- To understand the future market competition in the Venous thromboembolism (VTE) market.

Request for sample pages

"The one year incidence of recurrent venous thromboembolism was 5.3% (95% confidence interval 4.1% to 6.7%) in women and 9.5% (7.9% to 11.4%) in men."

Venous thromboembolism is a life-threatening medical condition that requires immediate medical treatment. Treatment primarily focuses on breaking the clots and preventing further formation of clots. Venous thromboembolism Treatment includes blood thinning agents such as Medication (Anticoagulants, Thrombolytic Agents, Factor Xa Inhibitors, Thrombin Inhibitors). Mechanical devices (compression stockings), and Surgical treatment (Pulmonary embolectomy, Vena caval interruption) are also used in advances stages of Venous thromboembolism.

However, the venous thromboembolism market is expected to expand in the near future, led by the development of novel oral anticoagulants (NOACs) to overcome the limitation of current treatment options and provide improved patient of care. NOACs offer major pharmacological benefits over current therapy. These include rapid onset and offset of action, predictable pharmacokinetics, and less drug interactions, which eliminate the need for regular coagulation monitoring associated with conventional anticoagulant therapy.
The dynamics of Venous Thromboembolism market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are working towards the development of new Venous Thromboembolism treatment therapies.

Venous thromboembolism Drug Companies

1. Tetherex Pharmaceuticals
2. Daiichi Sankyo
and many others.

Drugs that are involved are

1. SelK2
2. DS-1040b
And many others

Table of contents

1. Report Introduction
2. Venous Thromboembolism Market Overview at a Glance
3. Venous Thromboembolism Disease Background and Overview
4. Venous Thromboembolism Epidemiology and Patient Population
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4 Spain
5.2.5. United Kingdom
5.3. Japan
6. Venous Thromboembolism Treatment & Medical Practices
7. Marketed Therapies
7.1. Key Cross Competition
7.2. Fragmin: Eisai
7.3. Bevyxxa: Portola Pharmaceuticals
7.4. Savaysa: Daiichi Sankyo
8. Venous Thromboembolism Emerging Therapies
9. Venous Thromboembolism Market Size
10. Venous Thromboembolism 7MM: Country-Wise Market Analysis
10.1. United States
10.2. Germany
10.3. France
10.4. United Kingdom
10.5. Spain
10.6. Italy
10.7. Japan
11. Report Methodology
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight